Business Wire

Checkmate Pharmaceuticals Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade in the Treatment of Certain Types of Metastatic or Unresectable Melanoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals, Inc. (Checkmate), a clinical-stage biotechnology company focused on developing proprietary technology to harness the power of the immune ...
Nasdaq

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently ...
Nasdaq

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and ...

Opdivo is the first and only PD-1 inhibitor to demonstrate superior overall survival and progression-free survival in combination with chemotherapy when compared to chemotherapy alone in patients with ...
Business Wire

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, ...
Seeking Alpha

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class ...